Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.10.2022 | Case report

Antineoplastics

Herpes zoster meningoencephalitis and lack of efficacy: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Masuishi T, et al. A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer. Journal of Gastrointestinal Oncology 13: 1701-1710, No. 4, Aug 2022. Available from: URL: http://doi.org/10.21037/jgo-21-863 Masuishi T, et al. A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer. Journal of Gastrointestinal Oncology 13: 1701-1710, No. 4, Aug 2022. Available from: URL: http://​doi.​org/​10.​21037/​jgo-21-863
Metadaten
Titel
Antineoplastics
Herpes zoster meningoencephalitis and lack of efficacy: 3 case reports
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-25316-0

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Antipsychotics

Case report

Multiple drugs

Case report

Fluorescein

Case report

Cisplatin